Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: The prevalence of allergy to cocamidopropyl betaine (CAPB) in North America has not been previously reported.
Objective: The aim of this study was to report on the most recent data on allergy to CAPB and a related allergen, amidoamine (AA).
Methods: Data was collected by the North American Contact Dermatitis Group from consecutive patients presenting for patch testing for diagnosis of presumed allergic contact dermatitis (ACD) from January 1, 2001, through December 31, 2001.
Results: Of 975 patients tested, 15 were patch-test positive to CAPB, 25 had positive reactions to AA, and 18 had positive reactions to both CAPB and AA. The most frequent site of dermatitis from CAPB was the head and neck region.
Conclusion: In North America, both CAPB and AA are useful allergens for detecting ACD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2310/6620.2004.20410 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!